Additional file 3: Figure S1.

OCT4 and BIRC5 overexpression in clinical hepatocellular carcinoma (HCC) specimens. (A) Forty-nine pairs of cancer tissues and liver tissues were taken from clinical HCC patients. All patients underwent hepatectomy at the Eastern Hepatobiliary Surgery Hospital (Shanghai, China) between September 25, 2007, and September 30, 2009. The study patients were confirmed to have no distant metastases, detectable ascites, or chemotherapy and radiotherapy before surgery. The resected lesions were diagnosed pathologically as HCC after surgery. Paraffin-embedded consecutive sections were subjected to immunohistochemical examination for BIRC5 and OCT4 expression using the UltraSensitive Streptavidin Proxidase Kit (Fuzhou Maixin Biotechnology Development Co., Fuzhou, China), original magnification 200×. (B) OCT4 and BIRC5 expression levels were scored according to the percentages of positive cells counted within 5 high-power fields, positive cell percentages from <10% to <100% were defined as score 1 to 9, all cells that were negative were scored as zero. Patient with 2 or more than score 2 was qualified as positive case. The clinical study was performed after obtaining the informed consent from every patient and did not show the patients’ names.

Format: JPEG Size: 211KB Download file

Cao et al. BMC Cancer 2013 13:82   doi:10.1186/1471-2407-13-82